# Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

> **NCT05938478** · — · RECRUITING · sponsor: **University of California, San Diego** · enrollment: 900 (estimated)

## Conditions studied

- Atopic Dermatitis
- Eczema

## Interventions

- **DRUG:** Tralokinumab

## Key facts

- **NCT ID:** NCT05938478
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-08
- **Primary completion:** 2034-11-30
- **Final completion:** 2035-09-30
- **Target enrollment:** 900 (ESTIMATED)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938478, "Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05938478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*